Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 6/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | RAF1 | P04049 | 2/20 | 0.35 |
| ▸ | BRAF | P15056 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | USP1 | O94782 | 1/20 | 0.33 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18520544 | 0.89 | GRM2 (0.38) | DHODHGRM2ADORA1ADORA2ARAF1 | |
| SCHEMBL18520700 | 0.87 | PIM2 (0.40) | DHODHGRM2ADORA1ADORA2ARAF1 | |
| SCHEMBL18520517 | 0.86 | GRM2 (0.40) | DHODHGRM2ADORA1ADORA2A | |
| SCHEMBL18520536 | 0.83 | ALDH1A1 (0.40) | DHODHGRM2ADORA1ADORA2ARAF1 | |
| SCHEMBL18520426 | 0.82 | DHODH (0.39) | DHODHGRM2ADORA1ADORA2A | |
| SCHEMBL18520754 | 0.81 | CYP1A2 (0.42) | DHODHGRM2ADORA1ADORA2A | |
| SCHEMBL18520542 | 0.78 | KDM4E (0.39) | DHODHGRM2ADORA1ADORA2AKDR | |
| SCHEMBL18520709 | 0.78 | GRM2 (0.42) | DHODHGRM2ADORA1ADORA2AKDR | |
| SCHEMBL18520432 | 0.78 | GRM2 (0.42) | DHODHGRM2ADORA1ADORA2AKDR | |
| SCHEMBL18520596 | 0.76 | GRM2 (0.54) | DHODHGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10745356-B2 | Compositions and methods for treating tuberculosis | THE BROAD INSTITUTE, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190284140-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | THE BROAD INSTITUTE, INC. | 2019-09-19 | — | — | US | disclosed |
| US-10329257-B2 | Compositions and methods for treating tuberculosis | THE BROAD INSTITUTE, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| WO-2017027768-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | THE BROAD INSTITUTE, INC. (US) | 2017-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745356-B2 | Compositions and methods for treating tuberculosis | C5, IFNG, TERT | DHODH 471/4885GRM2 4698/4885HDAC4 567/4885 |
| US-10329257-B2 | Compositions and methods for treating tuberculosis | C5, IFNG, TERT | DHODH 471/4885GRM2 4698/4885HDAC4 567/4885 |
| US-20190284140-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | C5, IFNG, TERT | DHODH 471/4885GRM2 4698/4885HDAC4 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.